ENOV — Enovis Corporation

Summary of Enovis Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Sales: $589 million, up 5% year-over-year on a reported basis.
• Organic Revenue Growth: 3% overall; 6% in Recon and 1% in Prevention & Recovery (P&R).
• Days Adjusted Organic Growth: 6% at the company level; 8% in Recon and 3% in P&R.
• Adjusted Gross Margin: 62%, improved by 40 basis points year-over-year.
• Adjusted EBITDA Margin: 17.6%, down 10 basis points year-over-year.
• Adjusted Earnings Per Share: $0.89, representing a 10% underlying growth.
• Free Cash Flow: Improved by $16 million year-over-year, with expectations of greater than 25% conversion in 2026.

2. Strategic Updates and Business Highlights

• Innovation Focus: Continued advancement in the innovation pipeline with significant product launches, including the Arvis system, which is expected to drive growth in the shoulder segment.
• Market Share Gains: Notable growth in U.S. Recon, particularly in extremities (10% organic growth) and a strong international performance with double-digit growth in extremities.
• Operational Improvements: Changes in operating model and leadership, along with enhanced daily management and incentive alignment with strategic objectives.
• P&R Segment Growth: Driven by revenue cycle management and upper extremity bracing, with high single-digit growth in bone stimulation.

3. Forward Guidance and Outlook

• 2026 Guidance: Reaffirmed with expectations for even revenue distribution between the first and second halves of the year.
• Market Recovery: Anticipated recovery in international market volumes and continued growth in U.S. Recon driven by new products and account conversions.
• Strategic Focus: Emphasis on disciplined capital allocation and operational excellence to sustain profitable growth.

4. Bad News, Challenges, or Points of Concern

• Market Volatility: Acknowledgment of a dynamic macroeconomic environment, including geopolitical tensions affecting Middle East revenues and supply chain inflation.
• Tariff Impacts: Ongoing tariff costs, with $4 million incurred in the quarter, affecting margins.
• Selling Days Impact: Fewer selling days in Q1 represented a 240 basis point headwind to growth, though some will be recovered in Q2 and Q4.
• Competitive Pressures: Concerns about competition in the hip and knee markets, particularly from larger companies.

5. Notable Q&A Insights

• Durability of U.S. Recon Growth: Management expressed confidence in sustaining growth due to effective execution and product launches, but refrained from raising guidance due to market uncertainties.
• Free Cash Flow Outlook: Expected to improve as the year progresses, with Q1 typically showing negative cash flow due to bonus payouts and expense phasing.
• Arvis System Reception: Positive early feedback from surgeons and hospitals, with expectations of competitive conversions and enhanced pricing stability.
• Market Growth Rates: Management estimates U.S. hips at 3-4%, knees at 4-5%, and shoulders at 5-7%, indicating stable underlying demand despite external pressures.

This summary encapsulates the key points from the earnings call, highlighting Enovis's financial performance, strategic initiatives, and the challenges ahead as they navigate a complex market landscape.